Joseph P. Lyssikatos Plans to Sell Enliven Therapeutics Shares

Joseph P. Lyssikatos, an officer of Enliven Therapeutics, Inc., has filed a Form 144 indicating his intent to sell 12,500 common shares of the company. The shares, which are founder shares acquired on September 1, 2019, will be sold pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024. The sales are expected to occur around October 20, 2025, with an aggregate market value of approximately $267,625. The shares will be sold from The Lyssikatos Revocable Trust. In the past three months, Lyssikatos has sold a total of 25,000 shares for gross proceeds of $494,963.73. The sales will be executed through Jefferies LLC on the Nasdaq exchange.